001     202035
005     20210129220010.0
024 7 _ |a 10.1016/j.neuropharm.2012.06.040
|2 doi
024 7 _ |a 0028-3908
|2 ISSN
024 7 _ |a 1873-7064
|2 ISSN
024 7 _ |a WOS:000311250300023
|2 WOS
024 7 _ |a altmetric:2096452
|2 altmetric
024 7 _ |a pmid:22766391
|2 pmid
037 _ _ |a FZJ-2015-04324
082 _ _ |a 610
100 1 _ |a Winterer, Georg
|0 P:(DE-HGF)0
|b 0
|e Corresponding Author
245 _ _ |a Allosteric alpha-7 nicotinic receptor modulation and P50 sensory gating in schizophrenia: A proof-of-mechanism study
260 _ _ |a Amsterdam [u.a.]
|c 2013
|b Elsevier Science
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1435666446_1776
|2 PUB:(DE-HGF)
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|0 0
|2 EndNote
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a article
|2 DRIVER
520 _ _ |a In this multicenter, double-blind, placebo-controlled, randomized, four way cross-over proof-of-mechanism study, we tested the effect of the positive allosteric α7 nicotinic acetylcholine receptor (nAChR) modulator JNJ-39393406 in a key translational assay (sensory P50 gating) in 39 regularly smoking male patients with schizophrenia. All patients were clinically stable and JNJ-39393406 was administered as an adjunct treatment to antipsychotics. No indication was found that JNJ-39393406 has the potential to reverse basic deficits of information processing in schizophrenia (sensory P50 gating) or has a significant effect on other tested electrophysiological markers (MMN, P300 and quantitative resting EEG). Sensitivity analyses including severity of disease, baseline P50 gating, medication and gene variants of the CHRNA7 gene did not reveal any subgroups with consistent significant effects. It is discussed that potential positive effects in subgroups not present or not large enough in the current study or upon chronic dosing are possible, but unlikely to be developed.
536 _ _ |a 333 - Pathophysiological Mechanisms of Neurological and Psychiatric Diseases (POF2-333)
|0 G:(DE-HGF)POF2-333
|c POF2-333
|f POF II
|x 0
588 _ _ |a Dataset connected to CrossRef, juser.fz-juelich.de
700 1 _ |a Gallinat, Jürgen
|0 P:(DE-HGF)0
|b 1
700 1 _ |a Brinkmeyer, Jürgen
|0 P:(DE-HGF)0
|b 2
700 1 _ |a Musso, Francesco
|0 P:(DE-HGF)0
|b 3
700 1 _ |a Kornhuber, Johannes
|0 P:(DE-HGF)0
|b 4
700 1 _ |a Thuerauf, Norbert
|0 P:(DE-HGF)0
|b 5
700 1 _ |a Rujescu, Dan
|0 P:(DE-HGF)0
|b 6
700 1 _ |a Favis, Reyna
|0 P:(DE-HGF)0
|b 7
700 1 _ |a Sun, Yu
|0 P:(DE-HGF)0
|b 8
700 1 _ |a Franc, Monique A.
|0 P:(DE-HGF)0
|b 9
700 1 _ |a Ouwerkerk-Mahadevan, Sivi
|0 P:(DE-HGF)0
|b 10
700 1 _ |a Janssens, Luc
|0 P:(DE-HGF)0
|b 11
700 1 _ |a Timmers, Maarten
|0 P:(DE-HGF)0
|b 12
700 1 _ |a Streffer, Johannes R.
|0 P:(DE-HGF)0
|b 13
773 _ _ |a 10.1016/j.neuropharm.2012.06.040
|g Vol. 64, p. 197 - 204
|0 PERI:(DE-600)1500655-4
|p 197 - 204
|t Neuropharmacology
|v 64
|y 2013
|x 0028-3908
856 4 _ |u https://juser.fz-juelich.de/record/202035/files/1-s2.0-S0028390812002985-main.pdf
|y Restricted
856 4 _ |u https://juser.fz-juelich.de/record/202035/files/1-s2.0-S0028390812002985-main.gif?subformat=icon
|x icon
|y Restricted
856 4 _ |u https://juser.fz-juelich.de/record/202035/files/1-s2.0-S0028390812002985-main.jpg?subformat=icon-1440
|x icon-1440
|y Restricted
856 4 _ |u https://juser.fz-juelich.de/record/202035/files/1-s2.0-S0028390812002985-main.jpg?subformat=icon-180
|x icon-180
|y Restricted
856 4 _ |u https://juser.fz-juelich.de/record/202035/files/1-s2.0-S0028390812002985-main.jpg?subformat=icon-640
|x icon-640
|y Restricted
856 4 _ |u https://juser.fz-juelich.de/record/202035/files/1-s2.0-S0028390812002985-main.pdf?subformat=pdfa
|x pdfa
|y Restricted
909 C O |o oai:juser.fz-juelich.de:202035
|p VDB
910 1 _ |a Forschungszentrum Jülich GmbH
|0 I:(DE-588b)5008462-8
|k FZJ
|b 0
|6 P:(DE-HGF)0
910 1 _ |a Forschungszentrum Jülich GmbH
|0 I:(DE-588b)5008462-8
|k FZJ
|b 2
|6 P:(DE-HGF)0
913 2 _ |a DE-HGF
|b Key Technologies
|l Decoding the Human Brain
|1 G:(DE-HGF)POF3-570
|0 G:(DE-HGF)POF3-572
|2 G:(DE-HGF)POF3-500
|v (Dys-)function and Plasticity
|x 0
913 1 _ |a DE-HGF
|b Gesundheit
|l Funktion und Dysfunktion des Nervensystems
|1 G:(DE-HGF)POF2-330
|0 G:(DE-HGF)POF2-333
|2 G:(DE-HGF)POF2-300
|v Pathophysiological Mechanisms of Neurological and Psychiatric Diseases
|x 0
|4 G:(DE-HGF)POF
|3 G:(DE-HGF)POF2
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
915 _ _ |a WoS
|0 StatID:(DE-HGF)0110
|2 StatID
|b Science Citation Index
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Thomson Reuters Master Journal List
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
920 _ _ |l yes
920 1 _ |0 I:(DE-Juel1)INM-3-20090406
|k INM-3
|l Kognitive Neurowissenschaften
|x 0
920 1 _ |0 I:(DE-Juel1)INM-4-20090406
|k INM-4
|l Physik der Medizinischen Bildgebung
|x 1
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-Juel1)INM-3-20090406
980 _ _ |a I:(DE-Juel1)INM-4-20090406
980 _ _ |a UNRESTRICTED
981 _ _ |a I:(DE-Juel1)INM-4-20090406


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21